Current role and future scope of upadacitinib in dermatology

Upadacitinib, a selective Janus Kinase 1 (JAK1) inhibitor, has rapidly emerged as an important therapeutic option for a wide range of immune-mediated inflammatory conditions. Upadacitinib efficiently targets important pathways causing chronic inflammation by selectively blocking JAK1-dependent cytokine signaling. Clinical trials have demonstrated efficacy in atopic dermatitis (AD), hidradenitis suppurativa (HS), and psoriasis in cases of psoriatic arthritis. Real-world data reinforce these findings, and also in other dermatologic conditions such as vitiligo, lichen planus (LP), and alopecia areata (AA). Future scope includes biomarker-driven personalization, data comparison with next-generation biologics, long-term safety monitoring, and dose selection optimization to balance tolerability and efficacy across a range of patient populations.